Back to search
Double Expressor DLBCL
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Double Expressor DLBCL trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Double Expressor DLBCL trials you may qualify forEfficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in eld…
The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cere…
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
This is a prospective, single-arm, multicenter clinical study to evaluate the efficacy and safety of chidamide, rituximab combined with lenalidomide sequential…
This study is a phase II clinical trial and is divided into three stages. Stage 1: Chemotherapy-free phase. All subjects will receive "Serplulimab, Chidamide,…
Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3…